Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) during the month of Ramadan in patients with type 2 diabetes mellitus in Pakistani population—an observational study from a tertiary care center in Karachi

Sheikh, Aisha; Das, Bhagwan; Sattar, Saadia; Islam, Najmul

doi:10.1007/s12020-022-03290-7

Cited by 6 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven studies investigated various pharmacological agents, including insulin (2), DDP-4 inhibitors (1), and SGLT2 inhibitors (4; ►Table 3). [22][23][24][25][26][27][28] A Cochrane review was also pub-lished on the effects of various interventions during RF. 29 They will be discussed briefly below.…”

Section: Pharmacological Therapymentioning

confidence: 99%

“…Four studies examined their use during RF. [25][26][27][28] Samkari et al assessed the safety and tolerability of empagliflozin in T2D patients during Ramadan in a prospective cohort study conducted for adult Muslim T2D patients. 25 Patients were categorized into two subcohorts (control vs. empagliflozin).…”

Section: Pharmacological Therapymentioning

confidence: 99%

“…Additionally, the risk of confirmed hypoglycemia was significantly different between the two groups. Sheikh et al 26 reported an observational study of the use of empagliflozin during Ramadan in patients with T2D in a Pakistani population at a university hospital. Participants were older 21 years and on stable SGLT2 inhibitor doses starting at least 2 months before Ramadan.…”

Section: Pharmacological Therapymentioning

confidence: 99%

See 2 more Smart Citations

Diabetes and Ramadan Fasting (2023): The Year in Review

Abusahmin,

Abdelgadir,

Eledrisi

et al. 2024

Journal of Diabetes and Endocrine Practice

View full text Add to dashboard Cite

Introduction We aimed to provide an overview of the global literature production on diabetes and Ramadan in the past year (2023). Materials and Methods This is a narrative, nonsystematic review of the international literature from two major medical online databases (PubMed and Google Scholar) in 2023. The search term “Diabetes AND Ramadan fasting” was used, and the relevant literature was narrated in a concise thematic account. Results The publications spanned a vast array of topics related to diabetes and Ramadan fasting (RF), including physiology and nutrition, risk assessment stratification tools and their validation, assessments of safety and efficacy profiles of older and newer diabetes therapies, diabetes education, use of advanced technology for the treatment, and monitoring and impact on pregnancy. Some reports covered the interaction between Ramadan and COVID-19 concerning diabetes, pregnancy, complications, and unique characteristics of diabetes and fasting by young and older people. Conclusion The current narration presents this year's global scholarly production on the safety of fasting practices, care models, and patients' experiences and perspectives.

show abstract

Section: Pharmacological Therapymentioning

confidence: 99%

Section: Pharmacological Therapymentioning

confidence: 99%

Section: Pharmacological Therapymentioning

confidence: 99%

See 1 more Smart Citation

Diabetes and Ramadan Fasting (2023): The Year in Review

Abusahmin,

Abdelgadir,

Eledrisi

et al. 2024

Journal of Diabetes and Endocrine Practice

View full text Add to dashboard Cite

show abstract

“…Several research studies on the subject were published in 2022. [15][16][17][18][19][20] In one study, the efficacy and safety of empagliflozin in people with T2DM during RF were determined. 15 People with T2DM who took empagliflozin and sulfonylurea with or without metformin and dipeptidyl peptidase inhibitors (DPP-4) were recruited a month before Ramadan.…”

Section: Research Studiesmentioning

confidence: 99%

“…Another study examined the safety and efficacy of SGLT2-i in patients with T2DM in a real-life setting during Ramadan. 16 Of the 102 participants recruited, 82 completed the study. Most (52%) were males, with a mean age of 52.2 years and an average duration of T2DM of 11.2 years.…”

Section: Research Studiesmentioning

confidence: 99%

Ramadan Fasting and Diabetes (2022): The Year in Review

Hafidh

Besheya

Elmehdawi

et al. 2023

Journal of Diabetes and Endocrine Practice

View full text Add to dashboard Cite

Objectives The literature on the impact of Ramadan fasting (RF) on metabolic control and health in people with diabetes is widely spread in many journals making it not readily accessible to those interested in the subject. We aimed to provide a narrative overview of the global literature production in 1 year (2022) on diabetes and RF. Materials and Methods It is a narrative, non-systematic review of the international literature from a single major medical online database (i.e., PubMed) in one calendar year (2022). Relevant literature was narrated in a concise thematic account. Results Themes emerged from the review of the literature on RF published in 2022, including a couple of studies on the epidemiology of fasting in the real world by adults and children. Three studies involved some pathophysiological observations of metabolic and other biochemical markers. Several studies assessed the use and safety of different pharmacological therapeutic agents. Certain sulfonylureas, such as modified-release gliclazide, were considered safer than other sulfonylureas. Newer basal insulin analogs were studied in different geographical and socioeconomic settings (Gulf vs. South East Asia). The role of diabetes technology in Ramadan was the focus of several studies of insulin pumps and monitoring. Special themes were high-risk groups, pregnancy, acute complications, postbariatric surgery, and COVID-19 in Ramadan. Few studies examined the safety of sodium-glucose co-transporter-2 inhibitors as a class and individually during RF. Professional and patient perspectives released in 2022 included updated guidelines for adults and adolescents. Conclusions In 2022's medical literature, RF and diabetes continue to address epidemiology, the burden of diabetes care on fasting patients, and discussions of concerns of patients and healthcare professionals. Risk stratification and issues of high-risk patients are still in focus for children, adolescents, and adults. Approaches to effective management still gather evidence for newer pharmacological agents and diabetes technology.

show abstract